About Index Trending news
Analyze
Pricing
Sanofi

Sanofi

Sanofi

Sanofi is a global healthcare leader focused on patients' needs. Interactions with this account must comply with the Terms.

Elsewhere

Alexa global traffic share

Twitter followers

Employees

Unknown size

Locations
HQ
Headquarters
PE Hub

At least six funds interested in Sanofi European generic drugs unit: Le Figaro

Stock markets Health
Adweek

WPP Is the Big Winner In Pharma Giant Sanofi's $1 Billion Global Review

Advertising Strategy
Xconomy

Sanofi Shores Up Flu Vaccine Business With Protein Sciences Deal

Health Science
Xconomy

FDA OKs Eczema Injection; Owners Regeneron, Sanofi Set $37K Price

Health
Xconomy

Sanofi's Experience With Dengvaxia May Speed Development of Zika Vaccine

Health
frenchweb

Sanofi se refait une santé avec Google dans le diabète

The Verge , Xconomy

Alphabet and pharma company Sanofi are teaming up to work on new diabetes treatments

Health
VentureBeat

Alphabet and Sanofi in $500 million diabetes joint venture

Health
Business Insider

Verily and Sanofi just launched a new company to tackle diabetes care

Health
The Motley Fool , Silicon Beat

Sanofi's Bid for Medivation Is Too Low

The Motley Fool

Better Buy: MannKind Corporation vs. Sanofi

The Motley Fool

This Amgen News Could Be a Game-Changer in its Fight Against Sanofi and Regeneron Pharmaceuticals

$8,600,000 Venture capital (Series A)
FinSMEs , Xconomy

ImmuneXcite Completes $8.6M Series A-1 Financing

Health Funding
Xconomy

Amgen Bests Sanofi-Regeneron In PCSK9 Patent Case, Losers Vow Appeal

Health Legal
The Motley Fool

Instant Analysis: Regeneron Pharmaceuticals and Sanofi's Experimental Drug Bests an AbbVie Blockbuster

The Motley Fool

Sanofi Says Au Revoir to MannKind Corporation --

The Motley Fool

MannKind Corp.'s Stock Craters After Sanofi Throws in the Towel on Afrezza --

The Motley Fool

Sanofi Sets Its Sights on 2020 -- Here's What Investors Need to Know --

Xconomy

Ex-Sanofi CEO Gets $600M to Drug Hunt With Boston Pharma

Health Strategy Funding
The Motley Fool

Sanofi and Regeneron Hit Another Bullseye --